CGEM Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
57.3M
+6.6%
53.7M
-2.8%
55.3M
-0.6%
55.6M
-26.7%
75.8M
R&D
44.4M
+5.5%
42.1M
-1.9%
42.9M
+2.3%
42.0M
-31.2%
61.0M
SG&A
12.8M
+10.7%
11.6M
-6.0%
12.3M
-9.6%
13.6M
-7.7%
14.8M
Operating Income
-57254000
-6.6%
-53697000
+2.8%
-55259000
+0.6%
-55595000
+26.7%
-75798000
EBITDA
-57175000
-6.6%
-53618000
+2.8%
-55180000
+0.6%
-55516000
+26.7%
-75721000
Net Income
-53704000
-8.1%
-49661000
+2.1%
-50713000
-0.2%
-50610000
+27.8%
-70055000
EPS (Basic)
$-0.87
-16.0%
$-0.75
-53.1%
$-0.49
+43.0%
$-0.86
+27.7%
$-1.19
EPS (Diluted)
$-0.87
-16.0%
$-0.75
-53.1%
$-0.49
+43.0%
$-0.86
+27.7%
$-1.19
Shares (Diluted)
61.5M
+1.7%
60.5M
+2.1%
59.2M
+0.2%
59.1M
+0.1%
59.0M
Cullinan Therapeutics (CGEM) โ€” Financials